ImmuPharma (LON:IMM) Reaches New 12-Month Low – What’s Next?

ImmuPharma plc (LON:IMM – Get Free Report) shares reached a new 52-week low on Tuesday. The stock traded as low as GBX 2.51 and last traded at GBX 2.80, with a volume of 2,026,019 shares changing hands. The stock had previously closed at GBX 2.60.

ImmuPharma Trading Up 7.7%

The company’s 50-day moving average is GBX 3.54 and its two-hundred day moving average is GBX 4.54. The firm has a market cap of £17.50 million, a P/E ratio of -3.37 and a beta of 3.02.

ImmuPharma (LON:IMM – Get Free Report) last posted its quarterly earnings data on Tuesday, September 15th. The company reported GBX (0.84) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 559.87%. Research analysts anticipate that ImmuPharma plc will post -339.00 EPS for the current fiscal year.

ImmuPharma Company Profile

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Recommended Stories

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.